About Crossject
Crossject is a company based in Dijon (France) founded in 2001.. Crossject has raised $40.33 million across 6 funding rounds from investors including Rothschild & Co, GSK and European Union. The company has 108 employees as of December 31, 2024. Crossject offers products and services including ZENEO®. Crossject operates in a competitive market with competitors including scPharmaceuticals, Valeritas, CeQur, Vaxxas and Incline Therapeutics, among others.
- Headquarter Dijon, France
- Employees 108 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Crossject Sa
-
Annual Revenue
$0 (USD)-100as on Dec 31, 2024
-
Net Profit
$-13.29 M (USD)-48.12as on Dec 31, 2024
-
EBITDA
$-10.75 M (USD)-4.47as on Dec 31, 2024
-
Total Equity Funding
$40.33 M (USD)
in 6 rounds
-
Latest Funding Round
$55.39 K (USD), Grant
Aug 01, 2019
-
Investors
Rothschild & Co
& 6 more
-
Employee Count
108
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Crossject
Crossject is a publicly listed company on the EURONEXT with ticker symbol ALCJ in France, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Crossject
Crossject offers a comprehensive portfolio of products and services, including ZENEO®. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Needle-free device for delivering emergency medications quickly.
Funding Insights of Crossject
Crossject has successfully raised a total of $40.33M across 6 strategic funding rounds. The most recent funding activity was a Grant round of $55.39 thousand completed in August 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 6
- Last Round Grant — $55,392
- First Round First Round
- Investors Count 7
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug, 2019 | Amount | Grant - Crossject | Valuation |
investors |
|
| Jul, 2013 | Amount | Series A - Crossject | Valuation |
investors |
|
| Mar, 2010 | Amount | Series A - Crossject | Valuation | GSK |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Crossject
Crossject has secured backing from 7 investors, including institutional and venture fund investors. Prominent investors backing the company include Rothschild & Co, GSK and European Union. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
A Plus Finance is engaged in investment management and financing services.
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location | |
|
PE investment firm investing primarily in France
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Crossject
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Crossject
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Crossject Comparisons
Competitors of Crossject
Crossject operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as scPharmaceuticals, Valeritas, CeQur, Vaxxas and Incline Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Provider of a device for subcutaneous drug delivery for the treatment of bacterial infections and heart failure
|
|
| domain | founded_year | HQ Location |
Wearable insulin patch pumps are developed for transdermal delivery.
|
|
| domain | founded_year | HQ Location |
Wearable insulin delivery patches are developed for mealtime dosing.
|
|
| domain | founded_year | HQ Location |
Developer of vaccines to treat cancer and infectious diseases
|
|
| domain | founded_year | HQ Location |
Hospital-focused specialty pharmaceuticals are developed for acute pain management.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Crossject
Frequently Asked Questions about Crossject
When was Crossject founded?
Crossject was founded in 2001.
Where is Crossject located?
Crossject is headquartered in Dijon, France. It is registered at Dijon, Bourgogne-franche-comte, France.
Is Crossject a funded company?
Crossject is a funded company, having raised a total of $40.33M across 6 funding rounds to date. The company's 1st funding round was a Series A of $11.01M, raised on May 01, 2001.
How many employees does Crossject have?
As of Dec 31, 2024, the latest employee count at Crossject is 108.
What does Crossject do?
CROSSJECT developed a needle-free injection platform called Zeneo, which is designed to improve patients safety, claimed to provide comfort and to enable a better observance of treatments. The product is a pre-fillable, needle-free injection system that is claimed to deliver drugs intradermally, subcutaneously, and intramuscularly, the company is developing a portfolio of products combining well-known drugs with an innovative injection mode, particularly adapted to emergency situations and most chronic treatments, with a device adaptable to many specific situations.
Who are the top competitors of Crossject?
Crossject's top competitors include scPharmaceuticals, Vaxxas and CeQur.
What products or services does Crossject offer?
Crossject offers ZENEO®.
Is Crossject publicly traded?
Yes, Crossject is publicly traded on EURONEXT under the ticker symbol ALCJ.
Who are Crossject's investors?
Crossject has 7 investors. Key investors include Rothschild & Co, GSK, European Union, A Plus Finance, and Sofimac Investment Managers.
What is Crossject's ticker symbol?
The ticker symbol of Crossject is ALCJ on EURONEXT.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.